智通财经网·2026-02-05 02:54Core Viewpoint - Nocera Biopharma (09969) has seen a significant stock price increase following its earnings forecast, projecting a revenue of 2.37 billion yuan in 2025, representing a year-on-year growth of approximately 134% [1] Group 1: Financial Performance - The company anticipates achieving a net profit of around 630 million yuan in 2025, marking its first profit after losses [1] - The core product, Orelabrutinib, is expected to contribute significantly to revenue growth [1] - Two business development (BD) transactions completed in the year are also expected to be key drivers for rapid revenue growth in 2025 [1] Group 2: Clinical Development - Nocera Biopharma has completed patient enrollment for its Phase III clinical trial of the novel TYK2 inhibitor ICP-488 for the treatment of psoriasis, with a total of 383 patients enrolled [1] - This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of ICP-488 as a monotherapy for adult patients with moderate to severe plaque psoriasis [1] - The completion of patient enrollment marks a significant clinical advancement for ICP-488, potentially offering a new oral treatment option for psoriasis patients [1]